Trade Baxter International - BAX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.11 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Baxter International Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 42.64 |
Open* | 42.98 |
1-Year Change* | 7.29% |
Day's Range* | 42.57 - 42.98 |
52 wk Range | 31.01-50.21 |
Average Volume (10 days) | 4.24M |
Average Volume (3 months) | 87.75M |
Market Cap | 19.70B |
P/E Ratio | 607.45 |
Shares Outstanding | 507.32M |
Revenue | 14.82B |
EPS | 0.06 |
Dividend (Yield %) | 2.98661 |
Beta | 0.61 |
Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 42.64 | 1.11 | 2.67% | 41.53 | 42.73 | 41.53 |
Mar 26, 2024 | 41.48 | -0.12 | -0.29% | 41.60 | 41.87 | 41.18 |
Mar 25, 2024 | 41.72 | -0.23 | -0.55% | 41.95 | 42.27 | 41.46 |
Mar 22, 2024 | 41.87 | -0.01 | -0.02% | 41.88 | 42.12 | 41.53 |
Mar 21, 2024 | 41.88 | 0.09 | 0.22% | 41.79 | 42.29 | 41.39 |
Mar 20, 2024 | 41.77 | 0.11 | 0.26% | 41.66 | 42.09 | 41.57 |
Mar 19, 2024 | 41.88 | 0.64 | 1.55% | 41.24 | 41.92 | 41.24 |
Mar 18, 2024 | 41.47 | -0.02 | -0.05% | 41.49 | 41.87 | 41.17 |
Mar 15, 2024 | 41.55 | 0.30 | 0.73% | 41.25 | 41.83 | 41.25 |
Mar 14, 2024 | 41.98 | -0.30 | -0.71% | 42.28 | 42.53 | 41.59 |
Mar 13, 2024 | 42.62 | -0.27 | -0.63% | 42.89 | 43.29 | 42.30 |
Mar 12, 2024 | 42.83 | -0.17 | -0.40% | 43.00 | 43.25 | 42.71 |
Mar 11, 2024 | 43.42 | 0.17 | 0.39% | 43.25 | 43.87 | 43.25 |
Mar 8, 2024 | 43.70 | 0.56 | 1.30% | 43.14 | 43.95 | 43.13 |
Mar 7, 2024 | 43.42 | 0.45 | 1.05% | 42.97 | 43.62 | 42.97 |
Mar 6, 2024 | 42.91 | 0.79 | 1.88% | 42.12 | 42.96 | 41.99 |
Mar 5, 2024 | 42.36 | -0.69 | -1.60% | 43.05 | 43.83 | 42.10 |
Mar 4, 2024 | 42.41 | 1.71 | 4.20% | 40.70 | 42.58 | 40.56 |
Mar 1, 2024 | 40.95 | 0.24 | 0.59% | 40.71 | 41.15 | 40.18 |
Feb 29, 2024 | 40.81 | -0.34 | -0.83% | 41.15 | 41.29 | 40.51 |
Baxter International Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, April 25, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Baxter International Inc Earnings Release Q1 2024 Baxter International Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 1, 2024 | ||
Time (UTC) 14:00 | Country US
| Event Baxter International Inc Annual Shareholders Meeting Baxter International Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 15113 | 12784 | 11673 | 11362 | 11099 |
Revenue | 15113 | 12784 | 11673 | 11362 | 11099 |
Cost of Revenue, Total | 9690 | 7626 | 7038 | 6541 | 6305 |
Gross Profit | 5423 | 5158 | 4635 | 4821 | 4794 |
Total Operating Expense | 17207 | 11129 | 10213 | 10345 | 9492 |
Selling/General/Admin. Expenses, Total | 3609 | 2619 | 2357 | 2397 | 2387 |
Research & Development | 602 | 529 | 496 | 508 | 599 |
Unusual Expense (Income) | 3306 | 355 | 322 | 899 | 210 |
Other Operating Expenses, Total | -9 | ||||
Operating Income | -2094 | 1655 | 1460 | 1017 | 1607 |
Interest Income (Expense), Net Non-Operating | -400 | -170 | -170 | -124 | -28 |
Other, Net | 141 | -8 | 2 | 77 | 38 |
Net Income Before Taxes | -2353 | 1477 | 1292 | 970 | 1617 |
Net Income After Taxes | -2421 | 1295 | 1110 | 817 | 1345 |
Net Income Before Extra. Items | -2433 | 1284 | 1102 | 807 | 1345 |
Total Extraordinary Items | 0 | 0 | 194 | 201 | |
Net Income | -2433 | 1284 | 1102 | 1001 | 1546 |
Income Available to Common Excl. Extra. Items | -2433 | 1284 | 1102 | 807 | 1345 |
Income Available to Common Incl. Extra. Items | -2433 | 1284 | 1102 | 1001 | 1546 |
Diluted Net Income | -2433 | 1284 | 1102 | 1001 | 1546 |
Diluted Weighted Average Shares | 504 | 508 | 517 | 519 | 546 |
Diluted EPS Excluding Extraordinary Items | -4.82738 | 2.52756 | 2.13153 | 1.55491 | 2.46337 |
Dividends per Share - Common Stock Primary Issue | 1.15 | 1.085 | 0.955 | 0.85 | 0.73 |
Diluted Normalized EPS | 2.10317 | 3.0315 | 2.60928 | 2.84008 | 2.4359 |
Minority Interest | -12 | -11 | -8 | -10 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3707 | 3513 | 3887 | 3773 | 3594 |
Revenue | 3707 | 3513 | 3887 | 3773 | 3594 |
Cost of Revenue, Total | 2330 | 2206 | 2418 | 2626 | 2219 |
Gross Profit | 1377 | 1307 | 1469 | 1147 | 1375 |
Total Operating Expense | 3747 | 3384 | 3696 | 6572 | 3319 |
Selling/General/Admin. Expenses, Total | 823 | 766 | 986 | 782 | 811 |
Research & Development | 165 | 157 | 153 | 148 | 148 |
Unusual Expense (Income) | 377 | 203 | 139 | 2958 | 60 |
Operating Income | -40 | 129 | 191 | -2799 | 275 |
Interest Income (Expense), Net Non-Operating | -157 | -126 | -153 | -172 | -66 |
Other, Net | 14 | 11 | 186 | 5 | 10 |
Net Income Before Taxes | -183 | 14 | 224 | -2966 | 219 |
Net Income After Taxes | -193 | 0 | 185 | -2934 | 185 |
Minority Interest | -2 | -1 | -4 | -3 | -3 |
Net Income Before Extra. Items | -195 | -1 | 181 | -2937 | 182 |
Net Income | -141 | 44 | 181 | -2937 | 252 |
Income Available to Common Excl. Extra. Items | -195 | -1 | 181 | -2937 | 182 |
Income Available to Common Incl. Extra. Items | -141 | 44 | 181 | -2937 | 252 |
Diluted Net Income | -141 | 44 | 181 | -2937 | 252 |
Diluted Weighted Average Shares | 506 | 506 | 507 | 504 | 508 |
Diluted EPS Excluding Extraordinary Items | -0.38538 | -0.00198 | 0.357 | -5.82738 | 0.35827 |
Dividends per Share - Common Stock Primary Issue | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 |
Diluted Normalized EPS | 0.29051 | 0.31028 | 0.50296 | 0.43849 | 0.3937 |
Depreciation / Amortization | 52 | 52 | 58 | 81 | |
Total Extraordinary Items | 54 | 45 | 70 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 8011 | 8872 | 8411 | 7503 | 5959 |
Cash and Short Term Investments | 1718 | 2951 | 3730 | 3335 | 1838 |
Cash & Equivalents | 1718 | 2951 | 3730 | 3335 | 1838 |
Short Term Investments | |||||
Total Receivables, Net | 2752 | 2713 | 2077 | 1896 | 1840 |
Accounts Receivable - Trade, Net | 2752 | 2713 | 2077 | 1896 | 1840 |
Total Inventory | 2718 | 2453 | 1916 | 1653 | 1667 |
Prepaid Expenses | 424 | 365 | 346 | 230 | 210 |
Other Current Assets, Total | 399 | 390 | 342 | 389 | 404 |
Total Assets | 28287 | 33521 | 20019 | 18193 | 15720 |
Property/Plant/Equipment, Total - Net | 5529 | 5808 | 5325 | 5120 | 4530 |
Property/Plant/Equipment, Total - Gross | 11971 | 12358 | 11874 | 11268 | 10333 |
Accumulated Depreciation, Total | -6442 | -6550 | -6549 | -6148 | -5803 |
Goodwill, Net | 6843 | 9836 | 3217 | 3030 | 3002 |
Intangibles, Net | 6793 | 7792 | 1671 | 1471 | 1410 |
Other Long Term Assets, Total | 653 | 835 | 1038 | 762 | 599 |
Total Current Liabilities | 4745 | 4236 | 3333 | 3230 | 2814 |
Accounts Payable | 1139 | 1246 | 1043 | 892 | 998 |
Payable/Accrued | 571 | 638 | 704 | ||
Accrued Expenses | 1801 | 2087 | 1053 | 961 | 900 |
Notes Payable/Short Term Debt | 299 | 301 | 0 | 226 | 2 |
Current Port. of LT Debt/Capital Leases | 1105 | 210 | 406 | 315 | 2 |
Other Current Liabilities, Total | 401 | 392 | 260 | 198 | 208 |
Total Liabilities | 22454 | 24444 | 11330 | 10311 | 7876 |
Total Long Term Debt | 15232 | 17149 | 5786 | 4809 | 3481 |
Long Term Debt | 15170 | 17081 | 5722 | 4755 | 3481 |
Deferred Income Tax | 698 | 962 | 143 | 192 | 215 |
Minority Interest | 62 | 44 | 37 | 30 | 22 |
Other Liabilities, Total | 1717 | 2053 | 2031 | 2050 | 1344 |
Total Equity | 5833 | 9077 | 8689 | 7882 | 7844 |
Common Stock | 683 | 683 | 683 | 683 | 683 |
Additional Paid-In Capital | 6322 | 6197 | 6043 | 5955 | 5898 |
Retained Earnings (Accumulated Deficit) | 14050 | 17065 | 16328 | 15718 | 15075 |
Treasury Stock - Common | -11389 | -11488 | -11051 | -10764 | -9989 |
Other Equity, Total | -3833 | -3380 | -3314 | -3710 | -3823 |
Total Liabilities & Shareholders’ Equity | 28287 | 33521 | 20019 | 18193 | 15720 |
Total Common Shares Outstanding | 504.432 | 501.615 | 504.915 | 506.155 | 512.999 |
Note Receivable - Long Term | 211 | 224 | 222 | 231 | 176 |
Long Term Investments | 247 | 154 | 135 | 76 | 44 |
Capital Lease Obligations | 62 | 68 | 64 | 54 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 12034 | 8205 | 8099 | 8011 | 7810 |
Cash and Short Term Investments | 5788 | 1722 | 1673 | 1718 | 1601 |
Cash & Equivalents | 5788 | 1722 | 1673 | 1718 | 1601 |
Total Receivables, Net | 2553 | 2544 | 2639 | 2659 | 2555 |
Accounts Receivable - Trade, Net | 2553 | 2544 | 2639 | 2659 | 2555 |
Total Inventory | 2873 | 2897 | 2922 | 2718 | 2675 |
Prepaid Expenses | 816 | 805 | 861 | 912 | 976 |
Other Current Assets, Total | 4 | 237 | 4 | 4 | 3 |
Total Assets | 30656 | 27885 | 28291 | 28287 | 27965 |
Property/Plant/Equipment, Total - Net | 4797 | 5027 | 5554 | 5529 | 5345 |
Property/Plant/Equipment, Total - Gross | 10863 | 11028 | 11622 | 11421 | 11084 |
Accumulated Depreciation, Total | -6585 | -6534 | -6622 | -6442 | -6285 |
Goodwill, Net | 6407 | 6418 | 6868 | 6843 | 6639 |
Intangibles, Net | 6230 | 6470 | 6640 | 6793 | 6927 |
Other Long Term Assets, Total | 1034 | 1621 | 1011 | 1111 | 1244 |
Total Current Liabilities | 6209 | 5765 | 4760 | 4745 | 3708 |
Accounts Payable | 1246 | 1240 | 1290 | 1139 | 1234 |
Accrued Expenses | 2537 | 2120 | 2157 | 2202 | 2195 |
Notes Payable/Short Term Debt | 514 | 249 | 50 | 299 | 275 |
Current Port. of LT Debt/Capital Leases | 1912 | 1928 | 1103 | 1105 | 4 |
Total Liabilities | 22555 | 22316 | 22412 | 22454 | 22430 |
Total Long Term Debt | 14067 | 14306 | 15278 | 15232 | 16153 |
Long Term Debt | 14067 | 14306 | 15278 | 15232 | 16153 |
Minority Interest | 65 | 62 | 62 | 62 | 44 |
Other Liabilities, Total | 2214 | 2183 | 2312 | 2415 | 2525 |
Total Equity | 8101 | 5569 | 5879 | 5833 | 5535 |
Common Stock | 683 | 683 | 683 | 683 | 683 |
Additional Paid-In Capital | 6368 | 6341 | 6312 | 6322 | 6297 |
Retained Earnings (Accumulated Deficit) | 16015 | 13655 | 13947 | 14050 | 14015 |
Treasury Stock - Common | -11249 | -11296 | -11324 | -11389 | -11406 |
Other Equity, Total | -3716 | -3814 | -3739 | -3833 | -4054 |
Total Liabilities & Shareholders’ Equity | 30656 | 27885 | 28291 | 28287 | 27965 |
Total Common Shares Outstanding | 507.296 | 506.37 | 505.836 | 504.432 | 504.044 |
Note Receivable - Long Term | 154 | 144 | 119 | ||
Other Current Liabilities, Total | 0 | 228 | 160 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -2421 | 1295 | 1110 | 1011 | 1546 |
Cash From Operating Activities | 1211 | 2222 | 1868 | 2104 | 2017 |
Cash From Operating Activities | 1403 | 890 | 823 | 789 | 771 |
Deferred Taxes | -225 | -146 | -88 | -310 | -263 |
Non-Cash Items | 3477 | 344 | 295 | 1039 | 211 |
Cash Taxes Paid | 330 | 282 | 249 | 294 | 301 |
Cash Interest Paid | 355 | 145 | 137 | 103 | 94 |
Changes in Working Capital | -1023 | -161 | -272 | -425 | -248 |
Cash From Investing Activities | -931 | -11200 | -1179 | -1100 | -916 |
Capital Expenditures | -679 | -743 | -709 | -696 | -659 |
Other Investing Cash Flow Items, Total | -252 | -10457 | -470 | -404 | -257 |
Cash From Financing Activities | -1438 | 8245 | -345 | 498 | -2603 |
Financing Cash Flow Items | -61 | -138 | -52 | -48 | -33 |
Total Cash Dividends Paid | -573 | -530 | -473 | -423 | -376 |
Issuance (Retirement) of Stock, Net | 95 | -413 | -298 | -914 | -2194 |
Issuance (Retirement) of Debt, Net | -899 | 9326 | 478 | 1883 | 0 |
Foreign Exchange Effects | -76 | -47 | 57 | -5 | -63 |
Net Change in Cash | -1234 | -780 | 401 | 1497 | -1565 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 45 | -2421 | -2606 | 328 | 73 |
Cash From Operating Activities | 479 | 1211 | 772 | 482 | 208 |
Cash From Operating Activities | 319 | 1403 | 1069 | 735 | 380 |
Deferred Taxes | -50 | -225 | -174 | -87 | -55 |
Non-Cash Items | 35 | 3477 | 3365 | 64 | 34 |
Changes in Working Capital | 130 | -1023 | -882 | -558 | -224 |
Cash From Investing Activities | -170 | -931 | -675 | -491 | -304 |
Capital Expenditures | -172 | -679 | -479 | -311 | -140 |
Other Investing Cash Flow Items, Total | 2 | -252 | -196 | -180 | -164 |
Cash From Financing Activities | -372 | -1438 | -1319 | -1017 | -548 |
Financing Cash Flow Items | -10 | -61 | -51 | -30 | -25 |
Total Cash Dividends Paid | -146 | -573 | -427 | -281 | -140 |
Issuance (Retirement) of Stock, Net | 36 | 95 | 82 | 88 | 66 |
Issuance (Retirement) of Debt, Net | -252 | -899 | -923 | -794 | -449 |
Foreign Exchange Effects | 18 | -76 | -130 | -74 | -13 |
Net Change in Cash | -45 | -1234 | -1352 | -1100 | -657 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Baxter Company profile
About Baxter International Inc
Baxter International Inc. through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Baxter International Inc revenues increased 10% to $12.78B. Net income increased 17% to $1.28B. Revenues reflect Americas segment increase of 10% to $6.67B, APAC segment increase of 13% to $2.79B. Net income benefited from Americas segment income increase of 17% to $2.61B, APAC segment income increase of 5% to $623M. Dividend per share increased from $0.96 to $1.09.
Equity composition
Common Stock $1 Par, 03/11, 2B auth., 683,494,944 issd., Less 112,110,796 Shs. in Treas. @$6.1M. Insiders control approx. 0.15%. PO 6/86, 1.85M shares @$18.75 by Goldman Sachs. *FY'98-'01 are restated for disc. ops. 5/01, 2-for-1 stock split. *5/02, Co acquired Fusion Medical Technologies @ 0.1763 (2,507,881 shs. issd.).
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
Df2-1W
One Baxter Pkwy
DEERFIELD
ILLINOIS 60015
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com